Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

APLT
Applied Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
0.6009USD+22.408%(+0.1100)7,869,719
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:26:30 AM EDT
0.4989USD+1.630%(+0.0080)23,888
After-hours
May 16, 2025 4:56:30 PM EDT
0.6189USD+2.996%(+0.0180)128,345
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
01:35PM EST  Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.   GlobeNewswire Inc
Jan 26, 2022
07:43AM EST  Applied Therapeutics Says May Offer And Sell From Time To Time Common Stock Of Up To $100M   Benzinga
Jan 18, 2022
02:19PM EST  Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.   GlobeNewswire Inc
Jan 14, 2022
09:31AM EST  Therapeutics, Inc. (APLT) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations   PR Newswire
Jan 13, 2022
05:56PM EST  Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.   GlobeNewswire Inc
Jan 6, 2022
02:50PM EST  Applied Therapeutics Granted Orphan Designation For Treatment Of Sorbitol Dehydrogenase Deficiency   Benzinga
12:06PM EST  Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (Applied or the Company) (NASDAQ:APLT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 4, 2022
06:32AM EST  Barclays Downgrades Applied Therapeutics to Equal-Weight, Lowers Price Target to $7   Benzinga
Jan 3, 2022
02:39PM EST  Mid-Afternoon Market Update: Dow Surges 150 Points; Applied Therapeutics Shares Slide   Benzinga
12:09PM EST  Mid-Day Market Update: Gold Down 1%; Immix Biopharma Shares Spike Higher   Benzinga
10:06AM EST  Mid-Morning Market Update: Markets Edge Higher; Tesla Q4 Deliveries Top Estimates   Benzinga
07:01AM EST  Applied Therapeutics to Hold on Submitting a New Drug Application for its AT-007 for Treatment of Galactosemia Pending Additional Discussions with the FDA   Benzinga
07:00AM EST  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the AT-007 Galactosemia program.   GlobeNewswire Inc
Dec 16, 2021
07:40AM EST  Applied Therapeutics Begins Registrational Phase 2/3 Study Of AT-007 In SORD Deficiency   RTTNews
07:09AM EST  Applied Therapeutics Announces Initiation Of Registrational Phase 2/3 Study of AT-007 In SORD Deficiency   Benzinga
07:00AM EST  Applied Therapeutics Announces Initiation of Registrational Phase   GlobeNewswire Inc
Nov 23, 2021
08:10AM EST  The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug   Benzinga
Nov 21, 2021
03:05PM EST  The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week   Benzinga
Nov 18, 2021
07:00AM EST  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poster presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia.   GlobeNewswire Inc
Nov 12, 2021
07:27AM EST  Applied Therapeutics Q3 EPS $(1.09) Up From $(1.33) YoY   Benzinga
07:00AM EST  Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol   GlobeNewswire Inc
Oct 25, 2021
07:16AM EDT  Applied Therapeutics Reports Biomarker Data From A Pilot Trial Of AT-007 In Patients With SORD Deficiency.   RTTNews
07:02AM EDT  Applied Therapeutics Reports Biomarker Data From Pilot Trial Of AT-007 In SORD Deficiency; Says Showed Substantial And Significant Reduction In Sorbitol   Benzinga
07:00AM EDT  Applied Therapeutics Reports Biomarker Data from Pilot Trial of   GlobeNewswire Inc
Oct 18, 2021
07:14AM EDT  Applied Therapeutics Reports Additional Pediatric Biomarker Data From ACTION-Galactosemia Kids   Benzinga
07:00AM EDT  Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters   GlobeNewswire Inc
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 9, 2021
07:01AM EDT  Applied Therapeutics Reports Initial Pediatric Biomarker Data From ACTION-Galactosemia Kids; Co. Reports 'Substantial and statistically significant reduction in plasma galactitol'   Benzinga
07:00AM EDT  Substantial and statistically significant reduction in plasma galactitol   GlobeNewswire Inc
Aug 27, 2021
02:45PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 2%; Navios Maritime Acquisition Shares Climb On Merger News   Benzinga
01:35PM EDT  Shares of Applied Therapeutics Inc. (APLT) are slipping nearly 20% despite no stock-specific news to hurt the shares.   RTTNews
10:10AM EDT  Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit   Benzinga
05:01AM EDT  Goldman Sachs Downgrades Applied Therapeutics to Sell, Announces $10 Price Target   Benzinga
Aug 12, 2021
07:29AM EDT  Applied Therapeutics Q2 EPS $(0.99) Up From $(1.27) YoY   Benzinga
07:00AM EDT  NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing   GlobeNewswire Inc
Jun 28, 2021
07:00AM EDT  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company has joined the Russell Microcap Index. The newly reconstituted index took effect after the market close on Friday, June 25, 2021.   GlobeNewswire Inc
Jun 25, 2021
12:07PM EDT  Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association   Benzinga
12:06PM EDT  ~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the hearts ability to functionPeople with diabetes or pre-diabetes who have Diabetic Cardiomyopathy are at high risk for developing overt heart failure   GlobeNewswire Inc
Jun 21, 2021
07:00AM EDT  Applied Therapeutics to Present on Diabetic Cardiomyopathy and   GlobeNewswire Inc
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
07:18AM EDT  Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder   Benzinga
07:04AM EDT  Applied Therapeutics Says FDA Grants Fast Track Designation To AT-007 For Galactosemia   RTTNews
07:01AM EDT  Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia   Benzinga
07:00AM EDT  Applied Therapeutics Granted Fast Track Designation by FDA for   GlobeNewswire Inc
Jun 1, 2021
07:00AM EDT  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced todaythat it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 1:20 p.m. ET.   GlobeNewswire Inc
May 19, 2021
07:00AM EDT  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced todaythat it will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 at 10:00 a.m. ET.   GlobeNewswire Inc
May 11, 2021
07:22AM EDT  Applied Therapeutics Q1 EPS $(1.00) Down From $(0.59) YoY   Benzinga
07:00AM EDT  Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency   GlobeNewswire Inc
Apr 7, 2021
07:00AM EDT  Applied Therapeutics to Present Cross-Sectional Analysis of   GlobeNewswire Inc
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:09AM EDT  Applied Therapeutics Reports FY20 EPS $(4.28) Down From $(3.55) YoY   Benzinga
07:00AM EDT  AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA   GlobeNewswire Inc
Mar 16, 2021
07:00AM EDT  Applied Therapeutics to Host Virtual Rare Disease Forum   GlobeNewswire Inc
Feb 23, 2021
07:00AM EST  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced todaythat it will present at two upcoming investor conferences in March:   GlobeNewswire Inc
Feb 22, 2021
07:09AM EST  Applied Therapeutics Closes 3M Share Common Stock Offering at $23/Share   Benzinga
07:00AM EST  Applied Therapeutics, Inc. Announces Closing of Public Offering   GlobeNewswire Inc
Feb 12, 2021
08:13AM EST  Applied Therapeutics Raises $69M Via Equity   Benzinga
Feb 11, 2021
07:42PM EST  Applied Therapeutics Prices Public Offering Of 3 Mln Shares At $23.00/shr   RTTNews
06:52PM EST  Applied Therapeutics, Inc. Announces Pricing of Public Offering of   GlobeNewswire Inc
Feb 10, 2021
04:21PM EST  Applied Therapeutics Announces A 3M Share Common Stock Offering   Benzinga
04:08PM EST  Applied Therapeutics Reports 3M Share Offering Of Common Shares   Benzinga
04:07PM EST  Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares   GlobeNewswire Inc
Feb 4, 2021
06:58PM EST  National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Pluralsight, Inc., JELD-WEN Holding, Inc., and Applied Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966.   GlobeNewswire Inc
Feb 1, 2021
07:17AM EST  Applied Therapeutics: FDA Lifts Hold And AT-007 ACTION-Galactosemia Kids Pediatric Clinical Study To Begin   RTTNews
07:04AM EST  Applied Therapeutics Announces FDA Hold Lifted From its AT-007 ACTION-Galacrosemia Study, Study to Resume Immediately   Benzinga
07:00AM EST  Applied Therapeutics Announces Restart of Pediatric Galactosemia Study   GlobeNewswire Inc
Dec 15, 2020
08:09AM EST  Applied Therapeutics REports Will Be Added To NASDAQ Biotech Index, Effective Monday, Dec. 21, 2020   Benzinga
08:00AM EST  Applied Therapeutics to be Added to NASDAQ Biotechnology Index   GlobeNewswire Inc
Dec 9, 2020
08:22AM EST  Applied Therapeutics Announces Launch of Galactosemia Awareness And Education Initiative   Benzinga
08:22AM EST  Applied Therapeutics Announces Launch of Galactosemia Awareness   GlobeNewswire Inc
07:08AM EST  UPDATE: Applied Therapeutics Says Overall, Plasma Reduction In Galactitol Correlated With Brain Reduction In Galactitol   Benzinga
07:08AM EST  Applied Therapeutics Announces MRS Data From ACTION-Galactosemia Study   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
07:04AM EST  Applied Therapeutics Q3 EPS $(1.33) Down From $(0.63) YoY   Benzinga
07:00AM EST  Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)   GlobeNewswire Inc
Nov 9, 2020
07:00AM EST  Applied Therapeutics Announces Presentation of Pre-Clinical Data   GlobeNewswire Inc
Oct 21, 2020
07:08AM EDT  Applied Therapeutics To Present Data On AT-007 For Treatment Of Galactosemia At American Society Of Human Genetics (ASHG) 2020 Annual Meeting   Benzinga
07:00AM EDT  Applied Therapeutics to Present Data on AT-007 for the Treatment   GlobeNewswire Inc
Oct 8, 2020
10:40AM EDT  Why Applied Therapeutics Is Trading Higher Today   Benzinga
07:21AM EDT  Truist Securities Initiates Coverage On Applied Therapeutics with Buy Rating, Announces Price Target of $85   Benzinga
Oct 6, 2020
08:00AM EDT  SHAREHOLDER ALERT: APLT AND LEGN Being Investigated by Block &   GlobeNewswire Inc
Oct 5, 2020
01:00PM EDT  180 Life Science Corp. Announces New Board of Directors Appointments   GlobeNewswire Inc
Sep 24, 2020
08:24AM EDT  Applied Therapeutics: FDA Grants AT-007 Both Pediatric Rare Disease, Orphan Drug Designation For PMM2-CDG Treatment   RTTNews
08:08AM EDT  Applied Therapeutics Announces FDA Grants AT-007 Pediatric Rare Disease Designation And Orphan Designation For Treatment Of PMM2-CDG   Benzinga
08:00AM EDT  FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan   GlobeNewswire Inc
Sep 17, 2020
07:00AM EDT  Applied Therapeutics to Present Data on AT-001 for Treatment of   GlobeNewswire Inc
Sep 2, 2020
07:00AM EDT  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced todaythat it will present at two upcoming investor conferences in September:   GlobeNewswire Inc
Sep 1, 2020
01:54PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether Applied Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.   GlobeNewswire Inc
08:00AM EDT  SHAREHOLDER ALERT: Block & Leviton LLP Reminds Investors that it   GlobeNewswire Inc
Aug 29, 2020
07:44PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (Applied or the Company) (NASDAQ:APLT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 21, 2020
05:00PM EDT  Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.   GlobeNewswire Inc
08:00AM EDT  The Portnoy Law Firm advises Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.   GlobeNewswire Inc
Aug 20, 2020
05:30PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (Applied or the Company) (NASDAQ:APLT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 18, 2020
06:41PM EDT  SHAREHOLDER ALERT: Block & Leviton LLP Investigating Applied   GlobeNewswire Inc
05:30PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Aug 17, 2020
02:31PM EDT  Mid-Afternoon Market Update: Nasdaq Surges 100 Points; LMP Automotive Shares Climb Following Q2 Results   Benzinga
12:27PM EDT  Mid-Day Market Update: Gold Rises Over 2%; Unity Biotechnology Shares Plummet   Benzinga
10:59AM EDT  Shares of Applied Therapeutics Inc. (APLT) are losing more than 17 percent or $4.99 in Monday's morning trade at $24.25.   RTTNews
09:35AM EDT  Applied Therapeutics Says Co. Received Letter From FDA That Placed A Partial Clinical Hold On Action-Kids Study   Benzinga
Aug 11, 2020
07:19AM EDT  Applied Therapeutics Q2 EPS $(1.27) Down From $(0.60) YoY   Benzinga
07:17AM EDT  Applied Therapeutics Q2 Net Loss $28.1 Mln Or $1.27/Shr Vs Loss $8.4 Mln Or $0.60/Shr Last Year   RTTNews
07:00AM EDT  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2020.   GlobeNewswire Inc
Jul 17, 2020
07:13AM EDT  Applied Therapeutics To Present Data On AT-007 For Galactosemia At Galactosemia Foundation 2020 Virtual Conference   RTTNews
07:02AM EDT  Applied Therapeutics To Present Data On AT-007 For Treatment Of Galactosemia At Galactosemia Foundation 2020 Virtual Conference   Benzinga
07:00AM EDT  Applied Therapeutics to Present Data on AT-007 for Treatment of   GlobeNewswire Inc
Jul 13, 2020
12:26PM EDT  Applied Therapeutics Shares Fall To Session Low Following Tweet From STAT News' Adam Feuerstein '$APLT amends investor deck, bolstering accusations made by anonymous critic...' Includes Link To Article   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC